Jazz Pharmaceuticals Gets FDA Priority Review, August 25 PDUFA for Ziihera in HER2+ GEA
FDA accepted Jazz Pharmaceuticals’ BLA for Ziihera combinations in first-line HER2+ advanced or metastatic gastroesophageal adenocarcinoma with an August 25, 2026 PDUFA date under the Real-Time Oncology Review program. The filing relies on pivotal HERIZON-GEA-01 Phase 3 data of zanidatamab plus chemotherapy ± tislelizumab and carries Breakthrough Therapy designation.
1. FDA Acceptance and Priority Review
The FDA accepted Jazz Pharmaceuticals’ supplemental BLA for Ziihera combinations in first-line HER2+ advanced or metastatic gastroesophageal adenocarcinoma under the Real-Time Oncology Review program. A target action date of August 25, 2026 has been set to evaluate the submission.
2. HERIZON-GEA-01 Phase 3 Trial
The sBLA is supported by data from the HERIZON-GEA-01 trial, a global, randomized Phase 3 study of 914 patients evaluating zanidatamab plus fluoropyrimidine- and platinum-based chemotherapy with or without tislelizumab versus trastuzumab plus chemotherapy. Dual primary endpoints include progression-free survival per blinded independent central review and overall survival.
3. Breakthrough Therapy Designation
FDA granted Breakthrough Therapy designation for zanidatamab in combination with chemotherapy, with or without tislelizumab, for first-line HER2+ unresectable locally advanced or metastatic gastroesophageal adenocarcinoma. This status is intended to expedite development and review based on preliminary evidence of substantial improvement over available therapies.
4. Clinical and Commercial Implications
Approval would expand Ziihera’s label into a high-unmet-need first-line indication, potentially establishing zanidatamab as the HER2-targeted agent of choice in gastroesophageal adenocarcinoma. Positive regulatory outcome could drive significant revenue growth and competitive positioning for Jazz Pharmaceuticals in the oncology market.